Abstract
| Original language | English |
|---|---|
| Title of host publication | Vitamins and Hormones |
| Editors | Gerald Litwack |
| Place of Publication | UK |
| Publisher | Elsevier |
| Pages | 147-162 |
| Number of pages | 16 |
| Volume | 106 |
| ISBN (Print) | 9780128141168 |
| DOIs | |
| Publication status | Published - 5 Jun 2017 |
Publication series
| Name | Vitamins and Hormones |
|---|
Fingerprint
Cite this
}
Thyroid Hormone Receptor Antagonists; from Environmental Pollution to Novel Small Molecules. / Mackenzie, Louise.
Vitamins and Hormones. ed. / Gerald Litwack. Vol. 106 UK : Elsevier, 2017. p. 147-162 (Vitamins and Hormones).Research output: Chapter in Book/Conference proceeding with ISSN or ISBN › Chapter › Research
TY - CHAP
T1 - Thyroid Hormone Receptor Antagonists; from Environmental Pollution to Novel Small Molecules
AU - Mackenzie, Louise
PY - 2017/6/5
Y1 - 2017/6/5
N2 - hyroid hormone receptors (TRs) are nuclear receptors which control transcription, and thereby have effects in all cells within the body. TRs are an important regulator in many basic physiological processes including development, growth, metabolism, and cardiac function. The hyperthyroid condition results from an over production of thyroid hormones resulting in a continual stimulation of thyroid receptors which is detrimental for the patient. Therapies for hyperthyroidism are available, but there is a need for new small molecules that act as TR antagonists to treat hyperthyroidism. Many compounds exhibit TR antagonism and are considered detrimental to health. Some drugs in the clinic (most importantly, amiodarone) and environmental pollution exhibit TR antagonist properties and thus have the potential to induce hypothyroidism in some people. This chapter provides an overview of novel small molecules that have been specifically designed or screened for their TR antagonist activity as novel treatments for hyperthyroidism. While novel compounds have been identified, to date none have been developed sufficiently to enter clinical trials. Furthermore, a discussion on other sources of TR antagonists is discussed in terms of side effects of current drugs in the clinic as well as environmental pollution.
AB - hyroid hormone receptors (TRs) are nuclear receptors which control transcription, and thereby have effects in all cells within the body. TRs are an important regulator in many basic physiological processes including development, growth, metabolism, and cardiac function. The hyperthyroid condition results from an over production of thyroid hormones resulting in a continual stimulation of thyroid receptors which is detrimental for the patient. Therapies for hyperthyroidism are available, but there is a need for new small molecules that act as TR antagonists to treat hyperthyroidism. Many compounds exhibit TR antagonism and are considered detrimental to health. Some drugs in the clinic (most importantly, amiodarone) and environmental pollution exhibit TR antagonist properties and thus have the potential to induce hypothyroidism in some people. This chapter provides an overview of novel small molecules that have been specifically designed or screened for their TR antagonist activity as novel treatments for hyperthyroidism. While novel compounds have been identified, to date none have been developed sufficiently to enter clinical trials. Furthermore, a discussion on other sources of TR antagonists is discussed in terms of side effects of current drugs in the clinic as well as environmental pollution.
U2 - 10.1016/bs.vh.2017.04.004
DO - 10.1016/bs.vh.2017.04.004
M3 - Chapter
SN - 9780128141168
VL - 106
T3 - Vitamins and Hormones
SP - 147
EP - 162
BT - Vitamins and Hormones
A2 - Litwack, Gerald
PB - Elsevier
CY - UK
ER -